CW
DTIL icon

CrossGen Wealth’s Precision BioSciences DTIL Stock Holding History

CrossGen Wealth’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.86K Hold
1,000
– – 0.01% 165
2026
Q1 		$5.5K Hold
1,000
– – ﹤0.01% 162
2025
Q4 		$4.16K Buy
+1,000
New +$5.68K ﹤0.01% 163

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

CrossGen Wealth's DTIL Position: Q2 2026 in Review

CrossGen Wealth held its Precision BioSciences (DTIL) position steady in Q2 2026 at 1,000 shares worth $7.86K. The position accounts for 0.01% of the portfolio, ranked #165.

CrossGen Wealth first reported a position in DTIL in Q4 2025 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • CrossGen Wealth held 1,000 shares of Precision BioSciences worth $7.86K as of Q2 2026.
  • CrossGen Wealth left its Precision BioSciences share count unchanged in Q2 2026.
  • Precision BioSciences made up 0.01% of CrossGen Wealth's portfolio in Q2 2026, its #165 holding.
  • CrossGen Wealth first reported a position in Precision BioSciences in Q4 2025 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on CrossGen Wealth's 13F filing for Q2 2026, filed 24 Jul 2026.